Atengen, Inc.

Atengen, Inc. is a biotech startup focused on precision pan-cancer tumor killing. Their innovative therapeutic target is specifically expressed in tumor blood vessels of most types of solid tumors, distinguishing it from healthy organ blood vessels. Through cutting-edge technologies, Atengen has identified drug candidates that not only inhibit new blood vessel growth, but also lead to extensive tumor necrosis by targeting existing tumor blood vessels. This approach presents a significant breakthrough in the treatment of solid tumors, with the potential to revolutionize the field. As the company operates by targeting the tumor blood supply as opposed to the tumor cells directly, it can effectively address solid tumors in a tissue agnostic manner while maintaining a high level of specificity. However, there is not enough information available about the founding date, industries, headquarters, last investment, and last investment investors at this time.